Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting.
Overview
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL is a phase 2 interventional study registered as NCT06500273 by Allogene Therapeutics, with 250 participants planned, started 2024-06-18 and due to reach its primary completion in 2027-12. Interventions recorded: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Shares Allogene Therapeutics, Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TreatmentALLO-647
Shares Allogene Therapeutics, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialClinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Fludarabine, Cyclophosphamide and the tag pipeline.